Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical Trial
Journal of Clinical Oncology · 30.10.2026
DOI: 10.1200/jco-26-00578 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, online erschienen am 30.10.2026. Verfasst von Henrik Frederiksen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Odense, Denmark. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Purpose
Patients with hematologic cancer rate fatigue as their most frequent and severe unmet issue. Methylphenidate (MTP) has been reported to alleviate cancer-related fatigue (CRF) in some studies, but data from hematologic cancers are lacking. We investigated MTP for hematologic CRF.
Methods
Using a double-blinded, placebo-controlled, two-period, crossover design, 152 adult fatigued patients with hematologic cancer were randomly assigned to 6 weeks of either MTP or placebo, with a treatment-free week before the crossover. Eligibility required a Visual Analog Scale fatigue score ≥4 (range, 0-10), hemoglobin ≥8.0 g/dL, no chemotherapy within 8 weeks, and no concomitant psychopharmacologic treatment. The primary end point was the between-group difference in the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F) score from baseline to end of each period.
Results
The median age was 59.0 years (range, 21-83), 44% were women, the performance status was 0 in 57.3%, and 11% had received high-dose therapy. FACIT-F improved 8.9 points (95% CIs, 7.3 to 10.4) after MTP and 3.9 points (95% CI, 2.3 to 5.4) after placebo. The between-group difference of 5.0 points (95% CI, 2.8 to 7.2) was in favor of MTP. Reduced fatigue ratings in favor of MTP were also observed using other tools. Toxicity was mild, but more adverse events were reported during the MTP (N = 73; 57%) versus placebo (N = 52; 40%) periods.
Conclusion
MTP treatment alleviated fatigue and may be considered as a pharmacologic fatigue intervention in patients with hematologic cancer.
Autor:innen und Institutionen
- Department of Hematology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Public Health, University of Southern Denmark, Odense, Denmark.
- OPEN, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Henrik Frederiksen, Sören Möller, Dennis Lund Hansen, Mette Borg Clausen, Hans Beier Ommen, Eduardo Bruera
Zitieren
APA
Frederiksen, H., Gregersen, H., Möller, S., Hansen, D. L., Kjer Møller, J. J., Clausen, M. B., Poulsen, C. B., Ommen, H. B., Dessau-Arp, A., Hannig, L. H., Starklint, J., Groenvold, M., & Bruera, E. (2026). Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00578
Vancouver
Frederiksen H, Gregersen H, Möller S, Hansen DL, Kjer Møller JJ, Clausen MB, et al. Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-00578
BibTeX
@article{Frederiksen2026,
author = {Frederiksen, Henrik and Gregersen, Henrik and Möller, Sören and Hansen, Dennis Lund and Kjer Møller, Jens-Jakob and Clausen, Mette Borg and Poulsen, Christian Bjørn and Ommen, Hans Beier and Dessau-Arp, Andriette and Hannig, Louise Hur and Starklint, Jørn and Groenvold, Mogens and Bruera, Eduardo},
title = {Methylphenidate for Hematologic Cancer–Related Fatigue: A Randomized Clinical Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-00578}
}
EUVIMED